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Objective: To determine the early and intermediate-term outcome of the staged
repair used to treat children with pulmonary atresia with ventricular septal defect
and major aortopulmonary collateral arteries.
Methods: We reviewed a retrospective case series of 104 patients with this complex
lesion. Information was obtained from medical records and referring physicians.
Results: Of the 104 patients treated with the staged repair, 58 achieved completion
of anatomic repair. The 10-year mortality was 16.5%. In the patients with complete
repair, the median right-to-left ventricle pressure ratio was 0.5. The overall surgical
reoperation rate was 17%, and 15.5% of patients required postoperative interven-
tional cardiac catheterization. In the multivariate analysis, the number of collateral
vessels incorporated in the repair was found to be an independent risk factor for
postoperative mortality and an elevated right-to-left ventricle pressure ratio after
complete repair.
Conclusion: The staged repair can be successfully used to treat patients with
pulmonary atresia with ventricular septal defect and major aortopulmonary collat-
eral arteries. This method yields a relatively low mortality with good functional
results.
Pulmonary atresia with ventricular septal defect (VSD) and majoraortopulmonary collateral arteries (MAPCAs) is an uncommon formof complex congenital heart disease (Figure 1).1-3 Children with thislesion are treated using a staged repair at our institution. The objectiveof this study was to assess the early and intermediate term outcome ofthe staged repair in 104 pediatric patients with this disease. The main
outcomes of interest were early and intermediate-term mortality, right-to-left ven-
tricle pressure ratio (pRV/pLV) after complete repair, rate of surgical reoperation,
requirement for postoperative interventional cardiac catheterization, and the func-
tional status of survivors. We also sought to determine risk factors for unfavorable
postoperative outcomes.
Methods
Study Design and Patients
The study design was a retrospective case series involving chart review and questionnaire or
telephone contact with referring physicians. Between January 1983 and December 2000, 104
consecutive children with pulmonary atresia with VSD and MAPCAs were treated at our
institution using the staged repair. All patients who presented with this diagnosis were treated
and no patient was refused treatment. One patient who was diagnosed at birth died at 2 weeks
of age prior to any intervention. This patient was excluded in the multivariate analysis.
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Follow-up
Follow-up of all patients was performed through December 2000.
The median length of follow-up was 10.2 years.
Procedure
Details of the staged approach surgical repair and the management
strategy the staged approach used at our institution have been
previously described.4,5 In brief, our staged repair consists of 3
sequential steps (see Figure 2): Stage 1 involves palliative inter-
ventions (surgical or cardiac catheterization) to promote growth of
the true pulmonary arteries when present and/or to control exces-
sive pulmonary blood flow in cases with congestive heart failure.
Stage 2 involves unifocalization of MAPCAs in both lungs. Stage
3 involves completion of the anatomic repair with closure of the
VSD and establishment of continuity between the right ventricle
and the reconstructed pulmonary vasculature.
Outcome Measures
The variables selected for assessment of outcome were early
(in-hospital) and intermediate-term (10-year) mortality, pRV/pLV
after complete repair, rate of surgical reoperation, requirement for
postoperative interventional cardiac catheterization, and the func-
tional status of the survivors. The pRV/pLV was measured directly
in the operating room after complete repair. The pRV/pLV was
also determined indirectly, during postoperative follow-up by us-
ing tricuspid valve regurgitation velocity on echocardiography as
Figure 1. Pulmonary vascular supply in 2 patients with pulmonary atresia with ventricular septal defect and major
aortopulmonary collateral arteries (MAPCAs). A, Magnetic resonance angiogram demonstrating absence of
pulmonary arteries in the mediastinum. B, Descending aortic angiogram in the same patient demonstrating MAPCA
distribution to all lung segments. C, Pulmonary venous wedge angiogram demonstrating a hypoplastic pulmonary
artery. D, Magnetic resonance angiogram in the same patient demonstrating MAPCAs.
Gupta et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 6 1747
CH
D
an estimate of the right ventricular pressure, and directly, by
cardiac catheterization in the patients who required interventional
cardiac catheterization after stage 3 repair.
Data Analysis
After review of the data, we performed descriptive and adjusted
analysis. The descriptive analysis includes patient characteristics,
pulmonary vasculature characteristics, overall and stagewise mor-
tality, pRV/pLV achieved after complete repair, surgical reopera-
tion rate, and requirement for postoperative interventional cardiac
catheterization. In the adjusted analysis risk factors for prediction
of unfavorable outcomes (mortality and an elevated pRV/pLV 
0.55) were determined. The independent variables of interest in-
cluded several patient demographic and surgical factors. We per-
formed multivariate logistic regression to identify these risk fac-
tors. The acceptable level of significance used was P .05, and all
the statistical analysis was performed using the STATA statistical
software package.
Results
One hundred four consecutive patients (55 girls and 49
boys) with pulmonary atresia with VSD and MAPCAs were
included in the series. Table 1 describes the characteristics
of the pulmonary vasculature in the 104 patients. Seventeen
(16.5%) patients had associated intra- and extracardiac mal-
formations that were repaired at the time of stage 3 surgery.
Table 2 describes the patient characteristics and the associ-
ated cardiac malformations. Figure 3 shows the distribution
of patients in each stage of the repair.
TABLE 1. Characteristics of pulmonary vasculature in 104
patients with pulmonary atresia with VSD and MAPCAs
Type of pulmonary
vasculature 1 2 3
Predominant source
of pulmonary
circulation
MAPCAs Codominant
MAPCAs
plus PAs
PAs
Pulmonary arteries Absent Hypoplastic Good-sized
Pulmonary artery
size*
— 2 mm (1-3) 4 mm (3-6)
No. patients (n  104) 22 51 31
MAPCAs/patient* 3 (1-6) 3 (1-6) 2 (1-3)
VSD, Ventricular septal defect; MAPCAs, major aortopulmonary collateral
arteries; PA, pulmonary artery.
*Median (range).
Figure 2. Management algorithm for patients with pulmonary atresia with ventricular septal defect (VSD) and
major aortopulmonary collateral arteries (MAPCAs) based on the nature of pulmonary vascular supply.
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Stage 1
Sixty-three of the 104 patients (61%) underwent stage 1
repair. Patients in this group presented with either unaccept-
able cyanosis or intractable congestive heart in the early
neonatal period. Table 3 shows the palliative surgical and
interventional cardiac catheterization procedures used in
stage 1. The median age at stage 1 repair was 1 week (range
3 days to 22 years). After stage 1, 52 (82.5%) patients
progressed to stage 2 and 7 (11%) patients are currently
awaiting stage 2. Four (6%) deaths occurred in stage 1
repair.
Stage 2
A total of 92 patients underwent stage 2 repair (52 after
stage 1 and 40 without stage 1). The 40 patients who did not
require stage 1 repair prior to stage 2 included patients who
remained clinically stable in early infancy with acceptable
cyanosis and no significant congestive heart failure. The
median age at stage 2 was 4.4 months (range 1 month to 37
years) Of the 92 patients treated, 54 (59%) required bilateral
unifocalization and 38 (41%) required unilateral unifocal-
ization. In patients who required bilateral unifocalization,
the median time interval between surgery on the right and
left lung was 1 year (range 3 months5 years). The median
number of MAPCAs unifocalized in stage 2 repair was 3
(range 1-6). After stage 2, 58 (63%) patients progressed to
stage 3 and 24 (26%) patients are currently awaiting stage 3.
One patient was deemed inoperable for stage 3 repair be-
cause of prohibitively elevated pulmonary vascular resis-
tance. Eight (9%) deaths occurred in stage 2 repair.
Stage 3
A total of 58 patients underwent stage 3 repair. The median
age at stage 3 repair was 5.2 years (range 1-34 years). The
median time interval between stage 2 and stage 3 repair was
1.95 years (range 1-8.6 years). The median cardiac bypass
time during stage 3 surgery was 168 minutes (range 114-
255 minutes). The median aortic crossclamp time was 114
minutes (range 47-190 minutes). The cardiac bypass time
and aortic crossclamp time included repair of the associated
cardiac malformations.
Of the 58 patients who achieved complete repair, 27
(46%) originally had hypoplastic pulmonary arteries with
codominant MAPCA circulation, 22 (38%) had good-sized
pulmonary artery with a dominant (60%) pulmonary ar-
tery circulation, and 9 (15.5%) had absent true pulmonary
arteries with a dominant MAPCA pulmonary circulation.
Two (3%) patients required creation of an adjustable atrial
septal defect or fenestration of the VSD for pRV/pLV 
0.75. Five (8.5%) deaths occurred in stage 3 repair.
Mortality
Figure 1 demonstrates the timing of deaths in relation to the
surgical stage of repair. Excluding 1 patient who died prior
to any intervention, there were a total of 17 deaths in the
series and the overall 10-year mortality was 16.5%. The
in-hospital (same surgical admission) mortality was 11.5%
(12 deaths) and the late (after hospital discharge) mortality
was 5% (5 deaths). The mortality rate in stage 1 repair was
6%, 9% in stage 2, and 8.5% in stage 3.
Of the 12 in-hospital deaths, 2 occurred during interven-
tional cardiac catheterization after stage 1 repair, 2 resulted
from hypoxia induced by bronchospasm, 3 from suprasys-
temic pRV/pLV, 2 from bacterial sepsis, 1 from hypoxia
induced by clotted unifocalization shunt, and 2 from un-
known causes. Of the 5 late deaths, 1 resulted from liver
failure in a patient with associated Alagilles syndrome, 1
from suprasystemic pRV/pLV, 1 from hypoxia induced by
clotted unifocalization shunt, 1 from hypoxia induced by
pulmonary embolism, and 1 from unknown cause.
Morbidity
The median pRV/pLV obtained in the operating room im-
mediately after complete repair was 0.5 (range 0.15-1.0).
The median pRV/pLV estimated at follow-up visits by
echocardiography as described in the Methods section was
0.46 (range 0.3-1.0). The median pRV/pLV measured by
cardiac catheterization was 0.55 (range 0.35-1.0).
There were a total of 36 (17%) reoperations in the series.
The reoperation rate for stage 1 repair was 16% (10 proce-
dures). The indications for reoperation after stage 1 included
excessive cyanosis or intractable congestive heart failure
from excessive pulmonary blood flow. The reoperation rate
for stage 2 repair was 19.5% (18 procedures). The most
TABLE 2. Patient characteristics and associated cardiac
malformations in 104 patients with pulmonary atresia with
VSD and MAPCAs
Gender (n  104)
Girls, no. (%) 55 (53%)
Age at each stage of
repair, median (range)
Stage 1 1 week (3 days to 22 years)
Stage 2 4.4 months (1 month to 37 years)
Stage 3 5.2 years (1-34 years)
Associated cardiac
malformations (n  17)
Aortic insufficiency 11
Mitral insufficiency 2
Partial anomalous
pulmonary venous
repair
2
Intramural left
coronary artery
1
Coarctation of aorta 1
Patent foramen ovale 14
VSD, Ventricular septal defect; MAPCAs, major aortopulmonary collateral
arteries.
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common indication for reoperation after stage 2 was exces-
sive cyanosis secondary to thrombosis or stenosis of the
unifocalization shunt. The reoperation rate for stage 3 repair
was 14% (8 procedures). The indication for reoperation
after stage 3 was pRV/pLV 0.75 from stenosis of the right
ventricle to pulmonary artery homograft conduit.
Postoperatively there were 16 interventional cardiac
catheterization procedures in the entire group. This does not
include the catheterization interventions performed for stage
1 repair. Of the interventions, 15% occurred after stage 1,
70% after stage 2, and 15% after stage 3 repair. The lesions
treated by interventional cardiac catheterization included:
branch pulmonary artery stenosis in 9 patients (5 responded
favorably to balloon angioplasty and 4 required stent place-
ment in stenosis sites); MAPCAs stenosis in 5 patients (3
responded to balloon angioplasty and 2 required stent place-
Figure 3. Distribution of 104 patients with pulmonary atresia with ventricular septal defect and major aortopul-
monary collateral arteries in the staged repair.
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ment and unifocalization tube); stenosis in 2 patients (1
responded to balloon angioplasty and 1 required stent place-
ment) in the unifocalization tube.
The functional status of survivors was defined qualita-
tively by the New York Heart Association (NYHA) classi-
fication. Of the 53 survivors after complete repair, 47 (89%)
were in NYHA class I or II and were either full-time
students, were employed full-time, or were capable of full-
time work. Six (11%) patients were judged to be in NYHA
class III or IV with significant symptoms. The symptoms
that these patients were experiencing included recurrent and
refractory ventricular tachycardia or congestive heart failure
due to deterioration of right ventricular function.
Results of Multivariate Analysis
In the univariate analysis the number of MAPCAs included
in the unifocalization was found to significantly predict the
risk of death and of an elevated pRV/pLV  0.55 postop-
eratively. Patients with fewer than 3 MAPCAs included in
the repair were at higher risk for both unfavorable outcomes
when compared with those with more than 3 MAPCAs (P
.05). In the univariate analysis, independent factors such as
age and weight at first surgery, age at last surgery, sex of
patient, distribution of native pulmonary arteries, and sur-
gical variables such as duration of cardiac bypass time and
aortic crossclamp time were not found to be significant
predictors of mortality or of an elevated pRV/pLV. Because
of the small number of patients in each subgroup, meaning
comparison using multivariate analysis became difficult.
Discussion
This study reports our experience with the staged repair
used in the treatment of children with pulmonary atresia
with VSD and MAPCAs. We evaluated the early and inter-
mediate-term outcome of the staged repair by measuring
mortality, pRV/pLV after complete repair, surgical reopera-
tion rate, requirement for postoperative interventional cath-
eterization, and the functional status of survivors. In 104
patients with this complex lesion, the overall in-hospital
mortality was 11.5% and the overall 10-year mortality was
16.5%. The median pRV/pLV ratio after complete repair
was 0.5. The surgical reoperation rate was 17%, and only 16
procedures for interventional cardiac catheterization were
required postoperatively. Most survivors after complete re-
pair were in NYHA class I or II symptomatically.
The overall mortality rate observed in our series is com-
parable to that noted in previous studies.6-20 The pRV/pLV
is widely regarded as a surrogate measure of functional
status after complete anatomic repair of this lesion. The
pRV/pLV observed in our study is also comparable to that
reported in other large series.6-20 We believe that this fa-
vorable pRV/pLV, particularly in patients who had ex-
tremely hypoplastic true pulmonary arteries with relatively
few MAPCAs, is the result of the aggressive approach used
to encourage growth of the true pulmonary arteries and
aggressive recruitment of as many MAPCAs as possible in
the repair, resulting in a larger effective pulmonary vascu-
lature. In the univariate analysis we found that unifocaliza-
tion of fewer than 3 MAPCAs in the repair was significantly
associated with an increased likelihood of mortality and
pRV/pLV  0.55 (P  .05).
The overall surgical reoperation rate noted in our study
was 16%, which is slightly higher than that previously
reported.6,7,15-18 There are several possible explanations for
this. Because stages 1 and 2 of the repair are performed in
early infancy, the physiologic requirements of the patient
frequently change with growth. The most common indica-
tion for reoperation in after stages 1 and 2 was excessive
cyanosis in patients who had previously acceptable oxygen
saturations after surgery. These patient required reoperation
with insertion of larger unifocalization shunts. Another in-
dication for reoperation was pulmonary artery reconstruc-
tion in patients who did not respond favorably to interven-
tional catheterization procedures.
Several patients with extremely hypoplastic pulmonary
arteries required multiple surgeries to be successfully sal-
vaged. Remarkably, no reoperations were required for ste-
nosis in MAPCAs, all cases of which responded favorably
TABLE 3. Palliative surgical and interventional cardiac
catheterization interventions performed in stage 1 repair
Type of stage 1 intervention
No. of
patients
(n  63)
1. Intervention to increase
pulmonary blood flow
a. Surgical (n  50)
Aortopulmonary artery shunt 40
Right ventricle outflow tract
patch
7
Right ventricle to pulmonary
artery conduit
2
Pulmonary artery
reconstruction
1
b. Cardiac catheterization (n  8)
Pulmonary valvuloplasty 4
Right ventricle outflow tract
stent
3
Collateral stenting 1
2. Intervention to reduce pulmonary
blood flow
a. Surgical (n  14)
Collateral banding with
aortopulmonary artery
shunt
11
Collateral banding alone 3
b. Cardiac catheterization (n  1)
Collateral embolization 1
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to interventional cardiac catheterization techniques. Also,
very few reoperations were required after complete repair.
We believe this to be the result of the relatively late age of
stage 3 repair, which enables the use of larger-sized con-
duits thus reducing the requirement for subsequent revision.
The requirement for postoperative interventional cardiac
catheterization in our series was relatively low, only 16 pro-
cedures in the entire series. In our opinion, this is the result of
staging the repair in patients with this lesion. The use of the
lateral thoracotomy incision for performing the unifocalization
procedure not only provides excellent exposure of the MAP-
CAs but also enable greater flexibility in recruiting them into
the repair. This results in reduced torsion at the surgical anas-
tomosis sites with a lower rate of subsequent stenosis.
The limitations of this study include a relatively limited
follow-up period (median follow-up 10 years) and lack of
generalizability of results to all patients with pulmonary
atresia with VSD and MAPCAs. Follow-up of survivors
from this series is ongoing and longer follow-up data will be
available in the future. Because all patients in this study
were treated with the staged approach, direct comparison
with patients treated with the single-staged approach is
difficult. For meaningful comparison between these 2 ap-
proaches, randomized allocation of patients with pulmonary
atresia with VSD and MAPCAs to single-staged or staged
repair would be required.
In summary, the results of our study indicate that chil-
dren with pulmonary atresia with VSD and MAPCAs can be
successfully treated using the staged repair. In our experi-
ence the staged repair yields a relatively low mortality with
good functional results. There remains room for improve-
ment in the requirement for surgical reoperation. As our
experience with this approach has evolved, we have ob-
served a significant reduction in the associated mortality and
morbidity. We anticipate an improved quality of life with
reduced need for postoperative surgical and interventional
catheterization in patients treated with this approach in the
future.
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